Podcast: Expert exchanges – HRR in mPC
How are homologous recombination repair mutations (HRRm) reshaping care pathways in metastatic prostate cancer (mPC)? Host Alicia Morgans brings together global experts to explore the evolving science and clinical impact of HRRm testing – from biological foundations and testing innovations to disparities in access, treatment sequencing, and patient perspectives. Tune in for practical guidance as leading experts unpack how HRR insights are driving precision medicine and transforming treatment strategies across the prostate cancer continuum.
Episode 10
Gunhild von Amsberg on sequencing therapy in mPC
Episode 9
Alex Wyatt on what’s next in HRR testing
Episode 8
Tony Collier on genetic testing in mPC
Episode 7
Neal Shore on disparities in HRRm testing access
Episode 6
Karim Fizazi on ESMO 2025 highlights in HRR and PC
Episode 5
Bertrand Tombal on interpreting HRR results
Episode 4
Colin Pritchard on liquid vs tissue biopsy in mPC
Episode 3
Gerhardt Attard on the genetic landscape of mCRPC
Episode 2
Joaquin Mateo on advances in HRR testing
Episode 1
David Olmos on unlocking the HRR pathway in mPC
HRR testing: Key clinical considerations
Access our concise summary article for key insights from this podcast series – from early testing to gene‑specific treatment decisions.
Meet the host
Alicia Morgans, MD, MPH
Alicia Morgans is a Genitourinary Medical Oncologist and Director of the Adult Survivorship Program at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts, USA. She leads multiple clinical trials focused on treatment strategies and quality of life in prostate cancer and has contributed to treatment guideline panels for the American Urological Association and the American Heart Association.
Disclosures: Consulting engagements with Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Dendreon, Exact Sciences, Exelixis, Johnson & Johnson, Lantheus, Merck, Novartis, Pfizer, Sumitomo Pharma, Telix, and Tolmar. Research collaborations with Astellas, Bayer, Lantheus, Merck, Novartis, Pfizer, Sumitomo Pharma, and Telix.
This content has been developed independently by Medthority who previously received educational funding from Pfizer in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.